Ibsrela (tenapanor) is a prescription drug that’s used to treat irritable bowel syndrome with constipation. Ibsrela’s cost may depend on factors such as whether you have health insurance and the ...

Licensing revenue comprised just over $32 million of Ardelyx's top line, while product sales arrived at $22.3 million, with the latter comprised entirely of sales from Ardelyx's first commercialized ...

Ibsrela (tenapanor) is a brand-name oral tablet that’s prescribed for irritable bowel syndrome with constipation (IBS-C) in adults. The cost of the drug, with and without insurance, can depend on ...

Ibsrela (tenapanor) is a prescription drug used to treat irritable bowel syndrome with constipation (IBS-C) in adults. Ibsrela comes as an oral tablet. To learn more about Ibsrela’s uses, see the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ibsrela for IBS-C can cause diarrhea in about 16% of patients, but it usually goes away in about a week. Bloating and gas occur in about 3% of Ibsrela users, but exercise and drinking tea may help.

IBSRELA® (tenapanor) growth continued with $22.3 million in U.S. net sales revenue in Q3 2023 Revenue for Ardelyx’s first commercialized product, IBSRELA, continued a persistent growth pattern. Driven ...

The approval was based on two phase 3 trials which evaluated Ibsrela in over 1200 adults with IBS-C. Ibsrela ® (tenapanor) is now available for the treatment of irritable bowel syndrome with ...

IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than ...

(RTTNews) - Ardelyx Inc. (ARDX) today reported preliminary fourth quarter and full year 2025 product revenue, currently expected product revenue for 2026 and updated long-term outlook for IBSRELA, ...

Ardelyx (ARDX) shares continued to climb on Friday as Piper Sandler upgraded, noting that the company has reported better-than-expected preliminary sales figures for its bowel disease therapy Ibsrela, ...